{
  "nctId": "NCT02720757",
  "briefTitle": "Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)",
  "officialTitle": "Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice",
  "protocolDocument": {
    "nctId": "NCT02720757",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-04-21",
    "uploadDate": "2018-12-13T07:42",
    "size": 306847,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02720757/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 132,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-08-26",
    "completionDate": "2017-12-14",
    "primaryCompletionDate": "2017-12-14",
    "firstSubmitDate": "2016-03-03",
    "firstPostDate": "2016-03-28"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion criteria:\n\n1. Written informed consent prior to participation\n2. Female and male patients = 40 years of age\n3. Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and COPD GOLD guideline recommendation\n\nExclusion criteria:\n\n1. Patients with contraindications according to Spiolto® Respimat® SmPC\n2. Patients who have been treated with a Long-acting beta2 adrenoceptor agonist\\\\Long-acting muscarinic antagonist (LABA/LAMA) combination (free and fixed dose) in the previous 6 weeks.\n3. Patients continuing Long-acting beta2 adrenoceptor agonist Inhalative Corticosteroids (LABA-iCS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists\n4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks\n5. Pregnancy and lactation\n6. Patients currently listed for lung transplantation\n7. Current participation in any clinical trial or any other non-interventional study of a drug or device Further exclusion criteria apply",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "40 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Patients With Therapeutic Success After Approximately (Approx.) 6 Weeks After Baseline",
        "description": "\"Therapeutic success\" is defined as a 10-point increase of physical functioning (PF)-10 between Visit 1 (baseline) and Visit 2 (approx. 6 weeks later) using a PF questionnaire, which is a subdomain of the Short form (SF)-36 patient questionnaire. The PF-10 sub-domain consists of 10 questions evaluating the extent of experienced restrictions while conducting usual activities. Each question of the PF-10 can be answered with \"yes, limited a lot\", \"yes, limited a little\", or \"No, not limited at all\", with a score of 1, 2, or 3. The scores over the 10 questions will be summed, resulting in a value between 10 (a patient answering all questions with \"yes, limited a lot\") and 30 (a patient answering all questions with \"No, not limited at all\"). The final sum of the individual scores will be standardized to a range of 0 to 100 using the following formula: 100\\*(sum-10)/20.\n\nPercentage of patients with therapeutic success after approximately 6 weeks after baseline are presented",
        "timeFrame": "Visit 1 (baseline) and at Visit 2 (approx. 6 weeks later)"
      }
    ],
    "secondary": [
      {
        "measure": "Change in the PF-10 Score From Visit 1 (Baseline) to Visit 2 (Approx. 6 Weeks Later)",
        "description": "Change in PF-10 score was determined by taking into account the individual change of each patient between Visit 1 and Visit 2.\n\nPF questionnaire, is a sub-domain of the Short form (SF)-36 patient questionnaire. The PF-10 sub-domain consists of 10 questions evaluating the extent of experienced restrictions while conducting usual activities. Each question of the PF-10 can be answered with \"yes, limited a lot\", \"yes, limited a little\", or \"No, not limited at all\", with a score of 1, 2, or 3. The scores over the 10 questions will be summed, resulting in a value between 10 (a patient answering all questions with \"yes, limited a lot\") and 30 (a patient answering all questions with \"No, not limited at all\"). The final sum of the individual scores will be standardized to a range of 0 to 100 using the following formula: 100\\*(sum-10)/20.",
        "timeFrame": "Visit 1 (baseline) and at Visit 2 (approx. 6 weeks later)"
      },
      {
        "measure": "General Condition of the Patient Evaluated by the Physician: Physicians' Global Evaluation (PGE)-Score at Visit 1 (Baseline) and at Visit 2 (Approx. 6 Weeks Later)",
        "description": "The treating physician used the Physician's Global Evaluation (PGE) to evaluate the general condition of the patient on an 8-point ordinal scale from 1 (very poor) to 8(excellent). PGE will be completed before and approx. 6 weeks after treatment initiation.\n\nCount of patients with PGE score 2, 3, 4, 5, 6, 7, 8 are presented for Visit 1 and Visit 2.",
        "timeFrame": "Visit 1 (baseline) and at Visit 2 (approx. 6 weeks later)"
      },
      {
        "measure": "Patient Satisfaction With Spiolto® Respimat® - Overall Satisfaction",
        "description": "A patient satisfaction survey is completed at Visit 2, using a 7-point ordinal scale with divisions from very dissatisfied to very satisfied.\n\nCount of patients with divisions from very dissatisfied to very satisfied are presented.",
        "timeFrame": "Visit 2 (approx. 6 weeks post baseline)"
      },
      {
        "measure": "Patient Satisfaction With Spiolto® Respimat® - Satisfaction With Inhaling From the Respimat® Device",
        "description": "A patient satisfaction survey is completed at Visit 2, using a 7-point ordinal scale with divisions from very dissatisfied to very satisfied.\n\nCount of patients with divisions from very dissatisfied to very satisfied are presented.",
        "timeFrame": "Visit 2 (approx. 6 weeks post baseline)"
      },
      {
        "measure": "Patient Satisfaction With Spiolto® Respimat® - Satisfaction With Handling of the Respimat® Inhalation Device",
        "description": "A patient satisfaction survey is completed at Visit 2, using a 7-point ordinal scale with divisions from very dissatisfied to very satisfied.\n\nCount of patients with divisions from very dissatisfied to very satisfied are presented.",
        "timeFrame": "Visit 2 (approx. 6 weeks post baseline)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:28.188Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}